在阿尔茨海默氏病中向粉样蛋白疾病修饰疗法后,沿周周血管空间指数进行不变的早期扩散张力成像:初步研究
Tatsushi Oura1, Hiroyuki Tatekawa1, Akitoshi Takeda2
1Department of Diagnostic and Interventional Radiology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
medRxiv : the preprint server for health sciences
|May 19, 2025
概括
在接受lecanemab治疗的阿尔茨海默氏病患者中,周围血管空间 (DTI-ALPS) 的扩散张力成像指数没有变化. 需要对更大群体进行进一步的研究和更长的观察,以了解治疗期间的淋巴变化.
科学领域:
- 神经成像是一种神经成像.
- 神经学 神经学
- 生物标志物 生物标志物
背景情况:
- 缺少阿尔茨海默病 (AD) 治疗期间早期淋巴变化的纵向成像生物标志物.
- 针对粉样蛋白的疾病修饰疗法 (DMT) 正在出现,用于AD管理.
研究的目的:
- 为了调查扩散张力成像沿周脉空间 (DTI-ALPS) 指数是否可以检测在ADDMT期间的淋巴功能早期变化.
- 评估DTI-ALPS指数在开始lecanemab治疗的AD患者中.
主要方法:
- 13名阿迪参与者在基线和开始lecanemab后三个月接受了DTI.
- 自动化DTI-ALPS指数计算使用预定义的基于地图集的感兴趣区域.
- 统计分析包括同等性测试和配对的t测试;类内相关系数 (ICCs) 评估了可重复性.
主要成果:
- DTI-ALPS指数从基线 (1.515) 到三个月 (1.513) (p=0.94) 没有显著变化.
- 平均变化 (0.002) 在等效率范围内,证实了统计等效.
- 自动化处理显示出完美的平台内部 (ICC=1.00) 和优秀的跨平台 (ICC=0.99) 可靠性.
结论:
- 在AD患者的lecanemab治疗的前三个月内,DTI-ALPS指数没有检测到淋巴活动的变化.
- 在治疗开始后不久,DTI-ALPS可能无法检测到早期的淋巴细胞变化.
- 更大的队列和更长的随访是必要的,以阐明DTI-ALPS动态和AD治疗效应之间的时间关系.
相关概念视频
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...